These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 8701596)
1. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Kilbourne ED; Couch RB; Kasel JA; Keitel WA; Cate TR; Quarles JH; Grajower B; Pokorny BA; Johansson BE Vaccine; 1995 Dec; 13(18):1799-803. PubMed ID: 8701596 [TBL] [Abstract][Full Text] [Related]
2. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Powers DC; Kilbourne ED; Johansson BE Clin Diagn Lab Immunol; 1996 Sep; 3(5):511-6. PubMed ID: 8877127 [TBL] [Abstract][Full Text] [Related]
3. Neuraminidase inhibiting antibody responses in pigs differ between influenza A virus N2 lineages and by vaccine type. Sandbulte MR; Gauger PC; Kitikoon P; Chen H; Perez DR; Roth JA; Vincent AL Vaccine; 2016 Jul; 34(33):3773-9. PubMed ID: 27325350 [TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. Kilbourne ED J Infect Dis; 1976 Oct; 134(4):384-94. PubMed ID: 789791 [TBL] [Abstract][Full Text] [Related]
5. [Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza. II. Neuraminidase inhibiting antibodies (author's transl)]. Werner J; Kuwert EK; Stegmaier R; Simböck H Zentralbl Bakteriol A; 1980 Feb; 246(1):1-9. PubMed ID: 7424233 [TBL] [Abstract][Full Text] [Related]
6. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Johansson BE; Pokorny BA; Tiso VA Vaccine; 2002 Feb; 20(11-12):1670-4. PubMed ID: 11858877 [TBL] [Abstract][Full Text] [Related]
7. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. Kilbourne ED; Cerini CP; Khan MW; Mitchell JW; Ogra PL J Immunol; 1987 May; 138(9):3010-3. PubMed ID: 3571981 [TBL] [Abstract][Full Text] [Related]
8. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. Ogra PL; Chow T; Beutner KR; Rubi E; Strussenberg J; DeMello S; Rizzone C J Infect Dis; 1977 Apr; 135(4):499-506. PubMed ID: 856917 [TBL] [Abstract][Full Text] [Related]
9. Stability of neuraminidase in inactivated influenza vaccines. Sultana I; Yang K; Getie-Kebtie M; Couzens L; Markoff L; Alterman M; Eichelberger MC Vaccine; 2014 Apr; 32(19):2225-30. PubMed ID: 24613525 [TBL] [Abstract][Full Text] [Related]
10. Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Kendal AP; Bozeman FM; Ennis FA Infect Immun; 1980 Sep; 29(3):966-71. PubMed ID: 7429641 [TBL] [Abstract][Full Text] [Related]
11. [Antibody response to hemagglutinin and neuraminidase induced by an influenza subunit vaccine (author's transl)]. Kuwert E; Werner J; Franke G; Paulus W Zentralbl Bakteriol Orig A; 1979 Jun; 244(1):1-16. PubMed ID: 92113 [TBL] [Abstract][Full Text] [Related]
12. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949 [TBL] [Abstract][Full Text] [Related]
13. Reactogenicity and immunogenicity of whole and ether-Tween-split influenza A virus vaccines in volunteers. Jennings R; Clark A; Oxford JS; Hockley DJ; Potter CW J Infect Dis; 1978 Nov; 138(5):577-86. PubMed ID: 712115 [TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Hocart M; Grajower B; Donabedian A; Pokorny B; Whitaker C; Kilbourne ED Vaccine; 1995 Dec; 13(18):1793-8. PubMed ID: 8701595 [TBL] [Abstract][Full Text] [Related]
15. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination. Muhamed G; Greenbaum E; Zakay-Rones Z Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048 [TBL] [Abstract][Full Text] [Related]
16. Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Kendal AP; Noble GR; Dowdle WR J Infect Dis; 1977 Dec; 136 Suppl():S415-24. PubMed ID: 606765 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Hehme N; Engelmann H; Kuenzel W; Neumeier E; Saenger R Virus Res; 2004 Jul; 103(1-2):163-71. PubMed ID: 15163505 [TBL] [Abstract][Full Text] [Related]
18. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Johansson BE; Kilbourne ED Virology; 1996 Nov; 225(1):136-44. PubMed ID: 8918540 [TBL] [Abstract][Full Text] [Related]
19. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Johansson BE Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609 [TBL] [Abstract][Full Text] [Related]
20. Universal type/subtype-specific antibodies for quantitative analyses of neuraminidase in trivalent influenza vaccines. Xu K; Li C; Gravel C; Jiang Z; Jaentschke B; Van Domselaar G; Li X; Wang J Sci Rep; 2018 Jan; 8(1):1067. PubMed ID: 29348625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]